Reported 8 months ago
Genic Biopharma, a Taiwanese company, is one of the few that ventures into developing new drugs for pets and has sought approval from the US FDA. Their PTS302 injection for dogs with tumors has received drug registration in China and shown effectiveness, especially for melanoma. Genic's unique advantage lies in being able to serve nearly 16 types of cancer in dogs with a single drug registration. By conducting clinical trials on dogs, Genic Biopharma is making progress towards providing effective treatment options for canine cancer, particularly melanoma, in the near future with support from the FDA, which encourages and provides unique benefits for developing animal drugs.
Source: YAHOO